Latham & Watkins advised Syneos Health, Inc., the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), in its underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation of an aggregate of 7 million shares of the Company’s common stock at a price to the public of US$74.95 per share. The Selling Stockholders have also granted the underwriter a 30-day option to purchase up to 1,050,000 additional shares of common stock. The Offering closed on March 3, 2021.
Latham & Watkins LLP represented Syneos Health in the offering with a capital markets team led by New York partners Keith Halverstam and Adam Gelardi, with New York associates Will Clark and MacLane Taggart. Advice was also provided on tax matters by New York partners Elena Romanova and Jocelyn Noll, with New York associate Sam Yang.